Prescription drugs: “Make science work for America”
The availability of promising new drugs to improve or even save our lives depends on an important but little-known federal law, the Prescription Drug User Fee Act (PDUFA). This law will expire in September if Congress does not renew it this summer.
As someone who works with biomedical researchers and as a patient, I know firsthand how important PDUFA is to providing Americans with new drugs safely and in a timely manner. Before PDUFA, it often took years for a promising new drug to go through the government approval process, unnecessarily pushing treatments away from patients whose lives could be better with them. With the establishment of PDUFA over the past 30 years, the biopharmaceutical industry and the FDA have enjoyed a constructive relationship that has eliminated undue delays while ensuring drug safety and efficacy.
PDUFA’s drug screening and approval process works. We do not want the return of delays that deprive patients of the means to improve their lives. As an advocate and as a patient, I believe Congress should take action and reauthorize PDUFA as soon as possible, so we can continue to make science work for America.
Ken Gordon, Seattle, Executive Director, Northwest Association, Biomedical Research